10 key variables driving HealthTech M&A valuations in Europe in 2025

Based on current market trends, Nelson Advisors team experience and industry publications to date in 2025, here are 10 key variables driving HealthTech M&A valuations in Europe in 2025:

1) AI Integration and Innovation: Companies with proven and proprietary AI algorithms, especially those in diagnostics, drug discovery, and predictive analytics, are commanding premium valuations. Buyers are actively acquiring these technologies to gain a competitive edge and improve operational efficiency. AI is a dominant force, with firms lagging in its adoption facing a valuation discount.

2) Shift to Value-Based Care: As healthcare systems in Europe move away from a fee-for-service model, companies that enable this transition are becoming more attractive. This includes firms with technologies for remote patient monitoring, population health management, and other solutions that deliver measurable cost savings and improved patient outcomes. Acquiring companies that can demonstrate a clear return on investment in a value-based care environment is a key driver.

3) Strong Financial Metrics and Growth Profile: While many healthtech companies are not yet profitable, buyers are scrutinizing financial health. Higher multiples are awarded to companies with a strong, sustainable revenue growth trajectory, high gross margins, and a significant percentage of recurring revenue.

4) Intellectual Property (IP) Portfolio: A robust and defensible IP portfolio, including patents and proprietary technology, provides a significant competitive advantage. Companies with strong IP are viewed as less risky and are highly sought after, leading to higher valuations. This is particularly crucial in the highly competitive European market.

5) Favourable Economic and Regulatory Environment: The current economic and regulatory landscape is fueling deal activity. Abundant "dry powder" from private equity firms, along with a more business-friendly regulatory stance and a clearer framework for digital health tools (like the EU's AI Act), are giving buyers more confidence to invest.

6) Strategic Consolidation: Larger healthcare players are using M&A to consolidate their market presence, achieve economies of scale, and fill strategic gaps. This "string of pearls" strategy involves acquiring smaller, innovative companies to enhance core platforms, expand geographic reach, and strengthen product pipelines against upcoming patent cliffs.

7) Data Monetisation and Interoperability: The ability to ethically and efficiently leverage patient data is a key value driver. Companies with clean, actionable data and solutions that enable seamless interoperability with Electronic Health Records (EHRs) and other systems are commanding higher multiples.

8) Niche Specialisations and High-Growth Sub-sectors: Valuations can vary widely by sub-sector. Companies operating in high-growth, specialized areas such as robotics, advanced surgical solutions, and specific therapeutic areas like ophthalmology, oncology, and rare diseases are seeing strong interest and higher valuations.

9) Stage of Company Development: The maturity and stage of a company's development significantly impacts its valuation. More mature companies with established commercial traction and deeper product pipelines are highly sought after by buyers looking for less risk and a quicker return on investment.

10) Alternative Deal Structures: There's a growing preference for alternative deal structures, including earn-outs, royalties, licensing agreements, and joint ventures. These structures are used to share risk and finance innovation, especially in the biotech and diagnostics sectors where regulatory and reimbursement risks are high. This flexibility helps bridge valuation gaps between buyers and sellers.

To discuss how Nelson Advisors can help your HealthTech company, please email [email protected]